The rules will set the template for tax officials to understand the extent of profits that can be taxed, taking into consideration the foreign companies' sales in India, supply side factors and more
MNCs have underperformed Indian pharma market growth in the last 15 years
India has received the most interest from firms who are to set up or expand production facilities, followed by Vietnam, Mexico, Thailand and Indonesia
In this edition of Deal Central, we catch up with Navin Wadhwani, Head of Investment Banking (India) at JP Morgan, for his first on-camera interview after taking over as the deals spearhead at the firm. Wadhwani expects private equity funds to eclipse strategies when it comes to M&A activity in India in 2024 even as he sees the trend of big block deals to continue along with mega IPOs. Pharma/healthcare, financials, tech, infra and energy are his top sectoral picks
The about turn comes after several industrialists criticised the move, saying the government should focus on skilling people. Such rules would make Bengaluru less attractive to investors and companies, they had said
The clarification will be presented to the GST Council for approval once the law committee reaches a consensus on the matter
Patience is paramount. India is not the market where one can expect quick victories, and even if you did win, it’s no indicator of its sustainability. Understanding that customers can have diverse preferences and value systems is key. All this necessitates long-term commitment and a flexible, adaptive strategy